AGC Biologics to exit Berkeley CA plant by end of year
AGC Biologics is undertaking major expansions at sites in Seattle, Denmark and Japan, but the plant in Berkeley no longer fits with the CDMO’s growth strategy. The Berkeley, California clinical biomanufacturing plant will play no further part in the firm’s future, AGC Biologics management tol ...
Secure health data services firm Bowhead Health has won a startup pitch competition run jointly by the Xcelerate and Biopharm America conferences ...
Danish biopharma Lundbeck says it expects to launch the potential blockbuster migraine biologic eptinezumab early next year after agreeing to buy ...
GE Healthcare has teamed with cleanroom production firm Germfree to develop a modular biomanufacturing facility for emerging biotherapeutics and ...
BiomX has announced plans to construct a clinical facility in Israel capable of making host bacteria in a 20-40 liter bioreactor for the producti ...
Recent Tweets
-
RT @BioProInsider: #CDMO AGC Biologics to exit Berkeley CA plant by end of year. Site, bought from XOMA in 2012, no longer fits with g… https://t.co/jDifhLYTbB
23 hours ago
-
#CDMO AGC Biologics to exit Berkeley CA plant by end of year. Site, bought from XOMA in 2012, no longer fits with g… https://t.co/jDifhLYTbB
23 hours ago
-
RT @Dan5tanton: Modular facilities could prove greater than the sum of their parts with innovation increasing #biopharma interest i… https://t.co/tGZL8rOxcA
1 day ago
-
RT @Dan5tanton: ABEC has launched a single-use bioreactor system with a working volume of 6,000 L – three times that of industry’s… https://t.co/0W4uDsz2Xa
5 days ago
Trending
August Featured Report
BPI Theater at CPhI 2019 and BIO 2019
2019
Gyrolab Immunoassays: Streamlining Workflows Through Automation
Ask the Experts
Automated, Closed-Loop, Inline Monitoring of CAR-T Cells in a Production Process
BPI White Papers
Streamlining the Antibody Discovery Workflow at ModiQuest Research